Can The Proposed Antibiotic For Multidrug-Resistant Infections Fuel Innoviva's Revenue Growth?

Shares of Innoviva Inc. (INVA), a diversified holding company with a portfolio of royalties and other healthcare assets, have lost nearly 14% of their value year-to-date to trade around $11.

Related Keywords

United States , ,Glaxo Group ,Entasis Therapeutics Holdings ,Jolla Pharmaceutical Company ,Innoviva Inc ,Glaxo Group Limited ,Pneumonia ,Antibiotics ,Dr ,Cnva ,